<DOC>
	<DOCNO>NCT02971683</DOCNO>
	<brief_summary>Trial Evaluate Efficacy Safety Abatacept subcutaneous ( SC ) Combination With Standard Therapy Compared Standard Therapy Alone Improving Disease Activity Adults With Active Idiopathic Inflammatory Myopathy</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety Abatacept Combination With Standard Therapy Compared Standard Therapy Alone Improving Disease Activity Adults With Active Idiopathic Inflammatory Myopathy</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Diagnosis IIM use Bohan Peter classification criterion : ) Subjects dermatomyositis ( DM ) must also confirm myositisassociated rash ( Gottron 's papule heliotrope rash preferably confirm skin biopsy ) prior muscle biopsy diagnostic IIM positive test least one identify myositisassociated autoantibody ; ii ) Subjects IIM DM must also prior muscle biopsy diagnostic IIM positive test least one identify myositisassociated autoantibody Demonstrable muscle weakness measure MMT8 ≤ 135 unit 3 follow : ) MMT8 ≤ 125 unit ; ii ) Physician 's global assessment ( PGA ) visual analog scale ( VAS ) ≥2 cm ; iii ) Subject 's global assessment ( SGA ) VAS ≥2 cm ; iv ) HAQDI ≥ 0.5 ; v ) One muscle enzyme ( CK , aldolase , lactate dehydrogenase ( LDH ) , aspartate aminotransferase ( AST ) , ALT ) ≥ 1.3 time upper limit normal ( ULN ) ; vi ) MDAAT Extramuscular Global Activity VAS ≥2 cm Demonstration currently active IIM determine adjudication committee unless subject one following : ) active myositisassociated rash ( Gottron 's papule heliotrope rash ) , ii ) recent ( within 1 month prior sign informed consent ) biopsy , magnetic resonance imaging ( MRI ) , electromyogram ( EMG ) demonstrate active disease , iii ) elevate CK &gt; 5 time upper limit normal Active disease despite prior treatment corticosteroid , immunosuppressant , biologics determine investigator The subject must background standard treatment IIM . The standard treatment allow background treatment IIM include : ) Corticosteroids alone , ii ) One follow immunosuppressant : methotrexate , azathioprine , mycophenolate mofetil , tacrolimus , cyclosporine ( combination treatment allow ) , iii ) A combination corticosteroids one immunosuppressant . The subject must medication ( ) IIM 12 week prior randomization dose must stable 4 week prior randomization . Subjects druginduced myositis , Inclusion Body Myositis , cancerassociated myositis Subjects treat penicillamine zidovudine past 3 month Subjects treat rituximab past year biologic treatment Intravenous Immunoglobulin ( IVIG ) past 6 month . Subjects uncontrolled rapidly progressive interstitial lung disease Subjects severe muscle damage ( Myositis Damage Index &lt; 3/10 ) , permanent weakness due nonIIM cause , myositis cardiac involvement Subjects risk tuberculosis Subjects recent acute infection require antibiotic Subjects history chronic recurrent bacterial , viral systemic fungal infection Subjects present malignancy previous malignancy within last 5 year prior screen ( except document history cure nonmetastatic squamous basal cell skin carcinoma cervical carcinoma situ ) . Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>